All In Biotech

Drug Trial Radar · NCT04252066

A Global Prospective Observational Study of Women With Fabry Disease and Their Infants During Pregnancy and Breastfeeding

Last checked: Nov 20, 2026Latest source record: Oct 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

20

Planned (sponsor's estimate)

Start

Mar 18, 2025

Primary completion

Aug 2029

Study completion Feb 2030

Sponsor

Lead sponsor
Amicus TherapeuticsIndustry
Sponsor type
Industry
First posted
Feb 5, 2020

More drug trials from this sponsor

Design

Study type
Observational
FDA-regulated drug
Yes
Who can join
Female only
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a global prospective observational study of women with Fabry disease and their infants during pregnancy and/or breastfeeding. The study will evaluate outcomes of pregnancy and/or breastfeeding in women and infants exposed to migalastat.

Conditions

  • Fabry Disease

Interventions

  • migalastatDrug

    This is an observational study. Patients as described in Cohort 1 should have been exposed to at least 1 dose of migalastat during pregnancy and/or breastfeeding.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of major birth defectsTime frame: Through the pregnancy, an average of 40 weeks and up to 12 months of infant age

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Amicus Therapeutics, Inc. Pregnancy Registry

    Philadelphia, Pennsylvania · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.